Understanding Ipamorelin
Ipamorelin is a growth hormone secretagogue investigated for its ability to stimulate growth hormone release. The source distinguishes human intravenous pharmacokinetic research from unvalidated community-reported subcutaneous schedules.
Peptide Type
Growth hormone secretagogue
Primary Research Focus
Growth hormone release and pharmacokinetics
Human Research Route
Intravenous (IV) infusion
Approximate Terminal Half-Life
Approximately two hours in the cited human pharmacokinetic study
Evidence Context
Human IV research does not establish subcutaneous safety, dosing limits or fasting benefits.
IV Research Does Not Validate SC Use
The cited human pharmacokinetic study used intravenous infusion. Its findings cannot establish a proven subcutaneous maximum, saturation ceiling or community administration schedule.
Reported Administration Patterns
The source describes community-reported subcutaneous schedules. These examples have not been validated by the cited human IV pharmacokinetic research and are not treatment recommendations.
SC example
Per administration
Frequency
Daily total
Reported cycle
Week 1
100 mcg per day
Once daily or equally divided twice daily
100 mcg
Week 1
Weeks 2–3
200 mcg per day
Once daily or equally divided twice daily
200 mcg
Weeks 2–3
Weeks 4–12
200–300 mcg total per day
Once daily or equally divided twice daily
200–300 mcg
Weeks 4–12
Per administration
100 mcg per day
Frequency
Once daily or equally divided twice daily
Per administration
200 mcg per day
Frequency
Once daily or equally divided twice daily
Per administration
200–300 mcg total per day
Frequency
Once daily or equally divided twice daily
Reported cycle
Weeks 4–12
If a community report describes 300 mcg total daily divided twice, that means 150 mcg per administration, not 300 mcg each. A four-week break is also mentioned but remains unvalidated.
Unvalidated Subcutaneous Examples
Fasting, dose splitting, subcutaneous maximums and on/off cycles are not established by the cited IV study. No proven subcutaneous saturation ceiling is identified in the source.
Safety Considerations
The source notes that human subcutaneous safety and dose limits remain unestablished. Intravenous pharmacokinetic findings cannot independently validate community-reported subcutaneous practices.
Important Safety and Evidence Concerns
Storage and Monitoring
Storage
The cited human IV research does not establish a universal vial storage period.
Product Stability
No universal storage or discard period is established by the cited IV pharmacokinetic research.
Monitoring Considerations
Glucose, IGF-1 and edema are discussed as monitoring considerations.
Dose Interpretation
There is no proven subcutaneous saturation ceiling in the source. IV findings should not be used to validate community SC assumptions.
Example Concentration Calculations
The source provides three independently recomputed mathematical concentration examples. These are reference calculations only, not preparation or administration instructions.
Amount (mg)
Final volume (mL)
Concentration (mg/mL)
Per 1 U (mcg)
Per 10 U (mcg)
Concentration (mg/mL)
2.5
Additional source example: 10 mg / 3 mL = 3.333 mg/mL, 33.33 mcg per 1 U and 333.3 mcg per 10 U. U refers to a U-100 volume marking (1 U = 0.01 mL). These are mathematical examples only, not mixing or administration instructions.
What Does the Research Show?
The cited human pharmacokinetic research examined intravenous Ipamorelin infusion at five short exposure levels. It reported an approximate two-hour terminal half-life, but does not establish subcutaneous schedules or fasting benefits.
Human Pharmacokinetic Research
Human pharmacokinetic research examined Ipamorelin through intravenous infusion.
Five IV Infusion Levels
The cited study used five short intravenous infusion levels.
Approximate Two-Hour Half-Life
The study found an approximate two-hour terminal half-life. This does not establish subcutaneous dosing or fasting benefits.
Regulatory and Research Limitations
No Validated Subcutaneous Protocol
The cited human pharmacokinetic study used IV infusion and does not establish a validated subcutaneous maximum, saturation ceiling, safety profile or treatment schedule. Community-reported practices should not be interpreted as proven clinical protocols.
This page is for educational and research reference only. It is not medical advice or a recommendation to use Ipamorelin.
